KRAS and colorectal carcinoma: Furthermore, newly diagnosed KRAS and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations were found up to 4 months before radiological progression in two stage IV CRC patients receiving systemic therapy (115).